Could you lot be any more condescending, and yet clearly ignorant at the same time? And clearly you cannot read and/or did not actually watch the associated webinar. Yes a regarded eminent Professor of infectious disease called R327 efficacious with only 1% improvement. Nice FUD. LMAO.
And no zecs, the endpoints included safety as well as efficacy, which it also demonstrated. And you know where you can stick your "classic appeal-to-authority fallacy" expressed opinion of me - you wouldn't have the faintest. I am actually talking specifically about this study particularly and then you paint me as some advocate of wider poor trial standards. Peer review usually takes months, and that's after submission. This trial has only just finished. Athan has a significant list of publications to his name, Rather difficult to become a Professor in medicine without peer-reviewed publication (arguable too much focus) - but now our Professor is throwing that all to the wind for cash from Recce you imply. Again. LMAO.
That some of you lot "hold" is in all likelihood fiction for how much time you spend on these forums slating RCE. There is being (rightly) critical of the precise composite measures not being released (as I was myself), but then there is slinging FUD all day every day at the slightest area of ambiguity - again we all agree RCE should release the composite scores.
That you lot imply a well published Professor would put his long earnt career, no doubt at considerable sacrifice, at risk with overseeing and endorsing dodgy results in stark contrast to the rest of his (published) career is the very essence of ignorance.
RCE Price at posting:
40.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)